Danaher Corporation acquired Masimo Corporation for approximately $9.9 billion ($180.00 per share cash; total enterprise value including assumed indebtedness and net of acquired cash; ~18x estimated 2027 EBITDA), a transaction announced in February 2026, structured as all cash (merger).
Masimo Corporation operates in Diagnostics, is based in Irvine, California, USA. Masimo Corporation is a leading specialty diagnostics provider of pulse oximetry and other patient monitoring solutions, primarily in acute care settings, with advanced sensor technology and AI-enabled monitoring.
Masimo is a leader in pulse oximetry and other patient monitoring solutions, which combined with its trusted brand and differentiated technology will greatly strengthen Danaher's diagnostics franchise; Danaher sees opportunities to expand Masimo's reach using the Danaher Business System and its global scale.
expected accretive to adjusted diluted EPS by $0.15–$0.20 in the first full year and ~$0.70 in the fifth full year; ~18x estimated 2027 EBITDA (15x including full expected annual synergies); Masimo expected to deliver high-single-digit core revenue growth. standalone operating company within Danaher's Diagnostics segment (alongside Radiometer, Leica Biosystems, Cepheid and Beckman Coulter Diagnostics)
We are excited to welcome the Masimo team to Danaher. We've followed this innovative company for many years and see it as an exceptional strategic fit for Danaher. Masimo is a leader in pulse oximetry and other patient monitoring solutions, which combined with its trusted brand and differentiated technology, will greatly strengthen our diagnostics franchise.Rainer M. Blair, President and Chief Executive Officer, Danaher Corporation
Masimo's advanced sensor technology and AI-enabled monitoring bring powerful new capabilities to our diagnostics portfolio. Integrating these strengths into Danaher will create meaningful opportunities to innovate for clinicians and improve decision making in critical settings.Julie Sawyer Montgomery, Executive Vice President for Diagnostics, Danaher
Advisory firms were not disclosed for this transaction.